These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 7066167)

  • 1. Difference in bioavailability between two brands of 8-methoxypsoralen and its impact on the clinical response in psoriatic patients.
    Herfst MJ; De Wolff FA
    Br J Clin Pharmacol; 1982 Apr; 13(4):519-22. PubMed ID: 7066167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of bioavailability and phototoxicity of two oral preparations of 5-methoxypsoralen.
    Stolk LM; Siddiqui AH; Westerhof W; Cormane RH
    Br J Dermatol; 1985 Apr; 112(4):469-73. PubMed ID: 3994922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioavailability study of two different 8-methoxypsoralen (8-MOP) preparations in patients receiving PUVA therapy.
    Nørgaard M; Hueg B; Staberg B
    Photodermatol; 1985 Aug; 2(4):252-6. PubMed ID: 3903679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intraindividual and interindividual variability in 8-methoxypsoralen kinetics and effect in psoriatic patients.
    Herfst MJ; De Wolff FA
    Clin Pharmacol Ther; 1983 Jul; 34(1):117-24. PubMed ID: 6861433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 5-Methoxypsoralen (Bergapten) for photochemotherapy. Bioavailability, phototoxicity, and clinical efficacy in psoriasis of a new drug preparation.
    Tanew A; Ortel B; Rappersberger K; Hönigsmann H
    J Am Acad Dermatol; 1988 Feb; 18(2 Pt 1):333-8. PubMed ID: 3279089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A reappraisal of the use of 5-methoxypsoralen in the therapy of psoriasis.
    Calzavara-Pinton P; Ortel B; Carlino A; Honigsmann H; De Panfilis G
    Exp Dermatol; 1992 Jul; 1(1):46-51. PubMed ID: 1344660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacokinetic comparison of 3 8-methoxypsoralen preparations and clinical aspects].
    Walther T; Haustein UF; Quednow B; Meyer FP
    Hautarzt; 1990 Jun; 41(6):317-21. PubMed ID: 2380068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 5-Methoxypsoralen (Bergapten) in photochemotherapy of psoriasis.
    Hönigsmann H; Jaschke E; Gschnait F; Brenner W; Fritsch P; Wolff K
    Br J Dermatol; 1979 Oct; 101(4):369-78. PubMed ID: 508604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [8-Methoxypsoralen (8-MOP)-a new galenic form and its relation to 8-MOP serum levels (author's transl)].
    Nitsche V; Raff M; Bardach H
    Arch Dermatol Res; 1981; 271(1):11-7. PubMed ID: 7294879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical study of a new preparation of 8-methoxypsoralen in photochemotherapy.
    el-Mofty AM; el-Sawalhy H; el-Mofty M
    Int J Dermatol; 1994 Aug; 33(8):588-92. PubMed ID: 7960360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of psoriasis with psoralens and ultraviolet A. A double-blind comparison of 8-methoxypsoralen and 5-methoxypsoralen.
    Berg M; Ros AM
    Photodermatol Photoimmunol Photomed; 1994 Oct; 10(5):217-20. PubMed ID: 7880762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microenema of 8-methoxypsoralen in photochemotherapy of psoriasis.
    Siddiqui AH; Stolk L; Korthals Altes-Levij van Vinninghe HR; Kammeijer A; Cormane RH
    Arch Dermatol Res; 1982; 273(3-4):219-23. PubMed ID: 7165351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum levels of 8-methoxypsoralen in two different drug preparations: correlation with photosensitivity and UV-A dose requirements for photochemotherapy.
    Hönigsmann H; Jaschke E; Nitsche V; Brenner W; Rauschmeier W; Wolff K
    J Invest Dermatol; 1982 Oct; 79(4):233-6. PubMed ID: 7130741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Photochemotherapy (PUVA) and psoriasis: comparison of 8-MOP and 8-MOP/5-MOP.
    Langner A; Wolska H; Kowalski J; Duralska H; Murawska E
    Int J Dermatol; 1976 Nov; 15(9):688-9. PubMed ID: 977210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of 8-methoxypsoralen in serum and suction blister fluid.
    Lauharanta J; Juvakoski T; Kanerva L; Lassus A
    Arch Dermatol Res; 1982; 273(1-2):111-4. PubMed ID: 7184466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical pharmacokinetics of methoxsalen and other psoralens.
    de Wolff FA; Thomas TV
    Clin Pharmacokinet; 1986; 11(1):62-75. PubMed ID: 3512141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma levels of 8-methoxypsoralen and phototoxicity studies during PUVA treatment of psoriasis with meladinin tablets.
    Thune P
    Acta Derm Venereol; 1978; 58(2):149-51. PubMed ID: 76395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum concentration and phototoxic effect of methoxsalen in patients with psoriasis.
    Swanbeck G; Ehrsson H; Ehrnebo M; Wallin I; Jonsson L
    Clin Pharmacol Ther; 1979 Apr; 25(4):478-80. PubMed ID: 428192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Influence of retinoids on the bioavailability of methoxy-8-psoralen].
    Beani JC; Bonnot D; Berthod F; Boitard M; Reymond JL; Beriel H; Amblard P
    Ann Dermatol Venereol; 1991; 118(4):273-5. PubMed ID: 2069337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of methoxsalen dose on ultraviolet-A-induced erythema.
    Ibbotson SH; Dawe RS; Farr PM
    J Invest Dermatol; 2001 May; 116(5):813-5. PubMed ID: 11348476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.